Biomarkers in Ewing sarcoma: The promise and challenge of personalized medicine. A report from the children's oncology group

Frontiers in Oncology

Volumn 3 JUN, Issue , 2013, Pages

  Shukla, Neerav ^a   Schiffman, Joshua D ^b   Reed, Damon ^c   Davis, Ian J ^d   Womer, Richard B ^e   Lessnick, Stephen L ^b   Lawlor, Elizabeth R ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Ewing sarcoma; Predictive; Prognostic

Indexed keywords

CD56 ANTIGEN; CELL CYCLE PROTEIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CONNEXIN 43; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DESMOPLAKIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALAPTIN; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA 34A; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEOPHOSMIN; OLAPARIB; PROTEIN P53; PROTEIN ZO1; RNA BINDING PROTEIN EWS; SOMATOMEDIN C RECEPTOR; TELOMERASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

CANCER PROGNOSIS; CANCER SURVIVAL; EWING SARCOMA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 84891590949     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00141     Document Type: Review

References (115)

1. Abudu, A., Mangham, D. C., Reynolds, G. M., Pynsent, P. B., Tillman, R. M., Carter, S. R., et al. (1999). Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br. J. Cancer 79, 1185-1189. doi:10.1038/sj.bjc.6690190.
2. Altman, D. G., Mcshane, L. M., Sauerbrei, W., and Taube, S. E. (2012). Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med. 10:51. doi:10.1186/1741-7015-10-51.
3. Armengol, G., Tarkkanen, M., Virolainen, M., Forus, A., Valle, J., Bohling, T., et al. (1997). Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br. J. Cancer 75, 1403-1409. doi:10.1038/bjc.1997.242.
4. Ash, S., Luria, D., Cohen, I. J., Goshen, Y., Toledano, H., Issakov, J., et al. (2011). Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. Clin. Cancer Res. 17, 2900-2907. doi:10.1158/1078-0432.CCR-10-3069.
5. Asmane, I., Watkin, E., Alberti, L., Duc, A., Marec-Berard, P., Ray-Coquard, I., et al. (2012). Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur. J. Cancer 48, 3027-3035. doi:10.1016/j.ejca.2012.05.009.
6. Atzori, F., Tabernero, J., Cervantes, A., Prudkin, L., Andreu, J., Rodriguez-Braun, E., et al. (2011). A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17, 6304-6312. doi:10.1158/1078-0432.CCR-10-3336.
7. Avigad, S., Cohen, I. J., Zilberstein, J., Liberzon, E., Goshen, Y., Ash, S., et al. (2004). The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 100, 1053-1058. doi:10.1002/cncr.20059.
8. Bacci, G., Forni, C., Longhi, A., Ferrari, S., Donati, D., De Paolis, M., et al. (2004). Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur. J. Cancer 40, 73-83. doi:10.1016/j.ejca.2003.08.022.
9. Barr, F. G., and Meyer, W. H. (2010). Role of fusion subtype in Ewing sarcoma. J. Clin. Oncol. 28, 1973-1974. doi:10.1200/JCO.2009.27.2161.
10. Bennani-Baiti, I. M., Cooper, A., Lawlor, E. R., Kauer, M., Ban, J., Aryee, D. N., et al. (2010). Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin. Cancer Res. 16, 3769-3778. doi:10.1158/1078-0432.CCR-10-0558.
11. Berghuis, D., Santos, S. J., Baelde, H. J., Taminiau, A. H., Egeler, R. M., Schilham, M. W., et al. (2011). Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J. Pathol. 223, 347-357. doi:10.1002/path.2819.
12. Biondi, A., Valsecchi, M. G., Seriu, T., D'aniello, E., Willemse, M. J., Fasching, K., et al. (2000). Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 14, 1939-1943. doi:10.1038/sj.leu.2401922.
13. Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., et al. (2008). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 111, 5477-5485. doi:10.1182/blood-2008-01-132837.
14. Brenner, J. C., Feng, F. Y., Han, S., Patel, S., Goyal, S. V., Bou-Maroun, L. M., et al. (2012). PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72, 1608-1613. doi:10.1158/0008-5472.CAN-11-3648.
15. Brownhill, S. C., Taylor, C., and Burchill, S. A. (2007). Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT. Br. J. Cancer 96, 1914-1923. doi:10.1038/sj.bjc.6603819.
16. Bui, M. M., Han, G., Acs, G., Reed, D., Gonzalez, R. J., Pasha, T. L., et al. (2011). Connexin 43 is a potential prognostic biomarker for Ewing sarcoma/primitive neuroectodermal tumor. Sarcoma 2011, 971050. doi:10.1155/2011/971050.
17. Cheung, I. Y., Feng, Y., Danis, K., Shukla, N., Meyers, P., Ladanyi, M., et al. (2007). Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin. Cancer Res. 13, 6978-6983. doi:10.1158/1078-0432.CCR-07-1417.
18. Cotterill, S. J., Ahrens, S., Paulussen, M., Jurgens, H. F., Voute, P. A., Gadner, H., et al. (2000). Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J. Clin. Oncol. 18, 3108-3114.
19. Craft, A., Cotterill, S., Malcolm, A., Spooner, D., Grimer, R., Souhami, R., et al. (1998). Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J. Clin. Oncol. 16, 3628-3633.
20. de Alava, E., Antonescu, C. R., Panizo, A., Leung, D., Meyers, P. A., Huvos, A. G., et al. (2000). Prognostic impact of P53 status in Ewing sarcoma. Cancer 89, 783-792. doi:10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.3.CO;2-H.
21. de Alava, E., Kawai, A., Healey, J. H., Fligman, I., Meyers, P. A., Huvos, A. G., et al. (1998). EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16, 1248-1255.
22. De Gruttola, V. G., Clax, P., Demets, D. L., Downing, G. J., Ellenberg, S. S., Friedman, L., et al. (2001). Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control. Clin. Trials 22, 485-502. doi:10.1016/S0197-2456(01)00153-2.
23. Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165. doi:10.1038/359162a0.
24. Dubois, S. G., Epling, C. L., Teague, J., Matthay, K. K., and Sinclair, E. (2010). Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr. Blood Cancer 54, 13-18. doi:10.1002/pbc.22245.
25. Ewing, J. (1972). Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. CA Cancer J. Clin. 22, 95-98. doi:10.3322/canjclin.22.2.95.
26. Ferrari, S., Mercuri, M., Rosito, P., Mancini, A., Barbieri, E., Longhi, A., et al. (1998). Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J. Chemother. 10, 484-491.
27. Ferreira, B. I., Alonso, J., Carrillo, J., Acquadro, F., Largo, C., Suela, J., et al. (2008). Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma. Oncogene 27, 2084-2090. doi:10.1038/sj.onc.1210845.
28. Fletcher, C., Bridge, J., Hogendoorn, P., and Mertens, F. (2013). "Classification of tumours. pathology and genetics of tumours of soft tissue and bone," in World Health Organization, 4th Edn, eds C. D. M. Fletcher, J. A. Bridge, P. Hogendoorn, and F. Mertens (Lyon: IARC Press), 306-309.
29. Fuchs, B., Inwards, C. Y., and Janknecht, R. (2004). Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin. Cancer Res. 10, 1344-1353. doi:10.1158/1078-0432.CCR-03-0038.
30. Fujiwara, T., Fukushi, J., Yamamoto, S., Matsumoto, Y., Setsu, N., Oda, Y., et al. (2011). Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma. Am. J. Pathol. 179, 1157-1170. doi:10.1016/j.ajpath.2011.05.034.
31. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., et al. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575. doi:10.1038/nature11005.
32. Garofalo, C., Manara, M. C., Nicoletti, G., Marino, M. T., Lollini, P. L., Astolfi, A., et al. (2011). Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30, 2730-2740. doi:10.1038/onc.2010.640.
33. Grier, H. E., Krailo, M. D., Tarbell, N. J., Link, M. P., Fryer, C. J., Pritchard, D. J., et al. (2003). Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694-701. doi:10.1056/NEJMoa020890.
34. Hattinger, C. M., Rumpler, S., Strehl, S., Ambros, I. M., Zoubek, A., Potschger, U., et al. (1999). Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 24, 243-254. doi:10.1002/(SICI)1098-2264(199903)24:3<243::AID-GCC10>3.0.CO;2-A.
35. Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H. Jr., Kemeny, N. E., Jessup, J. M., et al. (1996). Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88, 1456-1466. doi:10.1093/jnci/88.20.1456.
36. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., Von Mehren, M., Joensuu, H., et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349. doi:10.1200/JCO.2003.04.190.
37. Ho, A. L., and Schwartz, G. K. (2011). Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J. Clin. Oncol. 29, 4581-4583. doi:10.1200/JCO.2011.38.2374.
38. Hodgson, D. R., Whittaker, R. D., Herath, A., Amakye, D., and Clack, G. (2009). Biomarkers in oncology drug development. Mol. Oncol. 3, 24-32. doi:10.1016/j.molonc.2008.12.002.
39. Hofbauer, S., Hamilton, G., Theyer, G., Wollmann, K., and Gabor, F. (1993). Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur. J. Cancer 29A, 241-245. doi:10.1016/0959-8049(93)90183-G.
40. Honoki, K., Stojanovski, E., Mcevoy, M., Fujii, H., Tsujiuchi, T., Kido, A., et al. (2007). Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis. Cancer 110, 1351-1360. doi:10.1002/cncr.22908.
41. Huang, H. Y., Illei, P. B., Zhao, Z., Mazumdar, M., Huvos, A. G., Healey, J. H., et al. (2005). Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J. Clin. Oncol. 23, 548-558. doi:10.1200/JCO.2005.02.081.
42. Italiano, A., Sung, Y. S., Zhang, L., Singer, S., Maki, R. G., Coindre, J. M., et al. (2012). High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer 51, 207-218. doi:10.1002/gcc.20945.
43. Jahromi, M. S., Jones, K. B., and Schiffman, J. D. (2011). Copy number alterations and methylation in Ewing's sarcoma. Sarcoma 2011, 362173. doi:10.1155/2011/362173.
44. Jahromi, M. S., Putnam, A. R., Druzgal, C., Wright, J., Spraker-Perlman, H., Kinsey, M., et al. (2012). Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet. 205, 391-404. doi:10.1016/j.cancergen.2012.05.012.
45. Ji, J., Kinders, R. J., Zhang, Y., Rubinstein, L., Kummar, S., Parchment, R. E., et al. (2011). Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS ONE 6:e26152. doi:10.1371/journal.pone.0026152.
46. Juergens, H., Daw, N. C., Geoerger, B., Ferrari, S., Villarroel, M., Aerts, I., et al. (2011). Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 29, 4534-4540. doi:10.1200/JCO.2010.33.0670.
47. Karski, E. E., Matthay, K. K., Neuhaus, J. M., Goldsby, R. E., and Dubois, S. G. (2013). Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 37, 29-33. doi:10.1016/j.canep.2012.08.006.
48. Kikuta, K., Tochigi, N., Shimoda, T., Yabe, H., Morioka, H., Toyama, Y., et al. (2009). Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin. Cancer Res. 15, 2885-2894. doi:10.1158/1078-0432.CCR-08-1913.
49. Kolb, E. A., Gorlick, R., Houghton, P. J., Morton, C. L., Lock, R., Carol, H., et al. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1190-1197. doi:10.1002/pbc.21450.
50. Kovar, H., Alonso, J., Aman, P., Aryee, D. N., Ban, J., Burchill, S. A., et al. (2012). The first European interdisciplinary Ewing sarcoma research summit. Front. Oncol. 2:54. doi:10.3389/fonc.2012.00054.
51. Kovar, H., Jug, G., Aryee, D. N., Zoubek, A., Ambros, P., Gruber, B., et al. (1997). Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 15, 2225-2232. doi:10.1038/sj.onc.1201397.
52. Kreuter, M., Paulussen, M., Boeckeler, J., Gerss, J., Buerger, H., Liebscher, C., et al. (2006). Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur. J. Cancer 42, 1904-1911. doi:10.1016/j.ejca.2006.01.063.
53. Kullendorff, C. M., Mertens, F., Donner, M., Wiebe, T., Akerman, M., and Mandahl, N. (1999). Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med. Pediatr. Oncol. 32, 79-83. doi:10.1002/(SICI)1096-911X(199902)32:2<79::AID-MPO1>3.0.CO;2-R.
54. Kung, F. H., Pratt, C. B., Vega, R. A., Jaffe, N., Strother, D., Schwenn, M., et al. (1993). Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 71, 1898-1903. doi:10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q.
55. La Thangue, N. B., and Kerr, D. J. (2011). Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587-596. doi:10.1038/nrclinonc.2011.121.
56. Le Deley, M. C., Delattre, O., Schaefer, K. L., Burchill, S. A., Koehler, G., Hogendoorn, P. C., et al. (2010). Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J. Clin. Oncol. 28, 1982-1988. doi:10.1200/JCO.2009.23.3585.
57. Lee, J., Hoang, B. H., Ziogas, A., and Zell, J. A. (2010). Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 116, 1964-1973. doi:10.1002/cncr.24937.
58. Lin, P. P., Jaffe, N., Herzog, C. E., Costelloe, C. M., Deavers, M. T., Kelly, J. S., et al. (2007). Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 109, 603-611. doi:10.1002/cncr.22412.
59. Lopez-Guerrero, J. A., Machado, I., Scotlandi, K., Noguera, R., Pellin, A., Navarro, S., et al. (2011). Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int. J. Cancer 128, 1139-1150. doi:10.1002/ijc.25424.
60. Luo, W., Gangwal, K., Sankar, S., Boucher, K. M., Thomas, D., and Lessnick, S. L. (2009). GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene 28, 4126-4132. doi:10.1038/onc.2009.262.
61. Machado, I., Lopez-Guerrero, J. A., Navarro, S., Alberghini, M., Scotlandi, K., Picci, P., et al. (2012). Epithelial cell adhesion molecules and epithelial mesenchymal transition (EMT) markers in Ewing's sarcoma family of tumors (ESFTs). Do they offer any prognostic significance? Virchows Arch. 461, 333-337. doi:10.1007/s00428-012-1288-x.
62. Mackintosh, C., Ordonez, J. L., Garcia-Dominguez, D. J., Sevillano, V., Llombart-Bosch, A., Szuhai, K., et al. (2012). 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 31, 1287-1298. doi:10.1038/onc.2011.317.
63. Maitra, A., Roberts, H., Weinberg, A. G., and Geradts, J. (2001). Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch. Pathol. Lab. Med. 125, 1207-1212.
64. Malempati, S., Weigel, B., Ingle, A. M., Ahern, C. H., Carroll, J. M., Roberts, C. T., et al. (2012). Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 30, 256-262. doi:10.1200/JCO.2011.37.4355.
65. Martin, R. C. 2nd, and Brennan, M. F. (2003). Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch. Surg. 138, 281-285. doi:10.1001/archsurg.138.3.281.
66. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., and Clark, G. M. (2005). Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 23, 9067-9072. doi:10.1200/JCO.2004.01.0454.
67. Meynet, O., Scotlandi, K., Pradelli, E., Manara, M. C., Colombo, M. P., Schmid-Antomarchi, H., et al. (2010). Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. Cancer Res. 70, 3730-3738. doi:10.1158/0008-5472.CAN-09-2837.
68. Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., et al. (1987). Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. 5, 1191-1198.
69. Nakatani, F., Ferracin, M., Manara, M. C., Ventura, S., Del Monaco, V., Ferrari, S., et al. (2012). miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J. Pathol. 226, 796-805. doi:10.1002/path.3007.
70. Nesbit, M. E. Jr., Gehan, E. A., Burgert, E. O. Jr., Vietti, T. J., Cangir, A., Tefft, M., et al. (1990). Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J. Clin. Oncol. 8, 1664-1674.
71. Oberlin, O., Deley, M. C., Bui, B. N., Gentet, J. C., Philip, T., Terrier, P., et al. (2001). Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br. J. Cancer 85, 1646-1654. doi:10.1054/bjoc.2001.2150.
72. Ohali, A., Avigad, S., Cohen, I. J., Meller, I., Kollender, Y., Issakov, J., et al. (2003). Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J. Clin. Oncol. 21, 3836-3843. doi:10.1200/JCO.2003.05.059.
73. Olmos, D., Postel-Vinay, S., Molife, L. R., Okuno, S. H., Schuetze, S. M., Paccagnella, M. L., et al. (2010a). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 11, 129-135. doi:10.1016/S1470-2045(09)70354-7.
74. Olmos, D., Tan, D. S., Jones, R. L., and Judson, I. R. (2010b). Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J. 16, 183-194. doi:10.1097/PPO.0b013e3181dbebf9.
75. Ozaki, T., Paulussen, M., Poremba, C., Brinkschmidt, C., Rerin, J., Ahrens, S., et al. (2001). Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 32, 164-171. doi:10.1002/gcc.1178.
76. Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K. P., Chawla, S. P., et al. (2011). R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541-4547. doi:10.1200/JCO.2010.34.0000.
77. Paulussen, M., Ahrens, S., Burdach, S., Craft, A., Dockhorn-Dworniczak, B., Dunst, J., et al. (1998). Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann. Oncol. 9, 275-281. doi:10.1023/A:1008208511815.
78. Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., et al. (2001). Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J. Clin. Oncol. 19, 1818-1829.
79. Perbal, B., Lazar, N., Zambelli, D., Lopez-Guerrero, J. A., Llombart-Bosch, A., Scotlandi, K., et al. (2009). Prognostic relevance of CCN3 in Ewing sarcoma. Hum. Pathol. 40, 1479-1486. doi:10.1016/j.humpath.2009.05.008.
80. Peter, M., Magdelenat, H., Michon, J., Melot, T., Oberlin, O., Zucker, J. M., et al. (1995). Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br. J. Cancer 72, 96-100. doi:10.1038/bjc.1995.283.
81. Pfleiderer, C., Zoubek, A., Gruber, B., Kronberger, M., Ambros, P. F., Lion, T., et al. (1995). Detection of tumour cells in peripheral blood and bone marrow from Ewing tumour patients by RT-PCR. Int. J. Cancer 64, 135-139. doi:10.1002/ijc.2910640211.
82. Pierron, G., Tirode, F., Lucchesi, C., Reynaud, S., Ballet, S., Cohen-Gogo, S., et al. (2012). A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat. Genet. 44, 461-466. doi:10.1038/ng.1107.
83. Pinto, A., Dickman, P., and Parham, D. (2011). Pathobiologic markers of the Ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma 2011, 856190. doi:10.1155/2011/856190.
84. Roberts, P., Burchill, S. A., Brownhill, S., Cullinane, C. J., Johnston, C., Griffiths, M. J., et al. (2008). Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. Genes Chromosomes Cancer 47, 207-220. doi:10.1002/gcc.20523.
85. Rodriguez-Galindo, C., Navid, F., Liu, T., Billups, C. A., Rao, B. N., and Krasin, M. J. (2008). Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann. Oncol. 19, 814-820. doi:10.1093/annonc/mdm521.
86. Rosen, G., Wollner, N., Tan, C., Wu, S. J., Hajdu, S. I., Cham, W., et al. (1974). Proceedings: disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 33, 384-393. doi:10.1002/1097-0142(197402)33:2<384::AID-CNCR2820330213>3.0.CO;2-T.
87. Saintigny, P., and Burger, J. A. (2012). Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med. 13, 287-297.
88. Sankar, S., and Lessnick, S. L. (2011). Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 204, 351-365. doi:10.1016/j.cancergen.2011.07.008.
89. Sauer, R., Jurgens, H., Burgers, J. M., Dunst, J., Hawlicek, R., and Michaelis, J. (1987). Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother. Oncol. 10, 101-110. doi:10.1016/S0167-8140(87)80052-X.
90. Savola, S., Klami, A., Tripathi, A., Niini, T., Serra, M., Picci, P., et al. (2009). Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9:17. doi:10.1186/1471-2407-9-17.
91. Saylors, R. L. III, Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L., et al. (2001). Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J. Clin. Oncol. 19, 3463-3469.
92. Schleiermacher, G., Peter, M., Oberlin, O., Philip, T., Rubie, H., Mechinaud, F., et al. (2003). Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J. Clin. Oncol. 21, 85-91. doi:10.1200/JCO.2003.03.006.
93. Scotlandi, K., Benini, S., Nanni, P., Lollini, P. L., Nicoletti, G., Landuzzi, L., et al. (1998). Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58, 4127-4131.
94. Scotlandi, K., Benini, S., Sarti, M., Serra, M., Lollini, P. L., Maurici, D., et al. (1996). Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 56, 4570-4574.
95. Scotlandi, K., Remondini, D., Castellani, G., Manara, M. C., Nardi, F., Cantiani, L., et al. (2009). Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J. Clin. Oncol. 27, 2209-2216. doi:10.1200/JCO.2008.19.2542.
96. Simon, R. M., Paik, S., and Hayes, D. F. (2009). Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101, 1446-1452. doi:10.1093/jnci/djp335.
97. Soldatenkov, V. A., Albor, A., Patel, B. K., Dreszer, R., Dritschilo, A., and Notario, V. (1999). Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor. Oncogene 18, 3954-3962. doi:10.1038/sj.onc.1202778.
98. Tap, W. D., Demetri, G., Barnette, P., Desai, J., Kavan, P., Tozer, R., et al. (2012). Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 30, 1849-1856. doi:10.1200/JCO.2011.37.2359.
99. Tarkkanen, M., Kiuru-Kuhlefelt, S., Blomqvist, C., Armengol, G., Bohling, T., Ekfors, T., et al. (1999). Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet. Cytogenet. 114, 35-41. doi:10.1016/S0165-4608(99)00031-X.
100. Toretsky, J. A., Steinberg, S. M., Thakar, M., Counts, D., Pironis, B., Parente, C., et al. (2001). Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 92, 2941-2947. doi:10.1002/1097-0142(20011201)92:11<2941::AIDCNCR10072>3.0.CO;2-C.
101. Tsuchiya, T., Sekine, K., Hinohara, S., Namiki, T., Nobori, T., and Kaneko, Y. (2000). Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet. 120, 91-98. doi:10.1016/S0165-4608(99)00255-1.
102. van Doorninck, J. A., Ji, L., Schaub, B., Shimada, H., Wing, M. R., Krailo, M. D., et al. (2010). Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J. Clin. Oncol. 28, 1989-1994. doi:10.1200/JCO.2009.24.5845.
103. van Maldegem, A. M., Hogendoorn, P. C., and Hassan, A. B. (2012). The clinical use of biomarkers as prognostic factors in Ewing sarcoma. Clin. Sarcoma Res. 2, 7. doi:10.1186/2045-3329-2-7.
104. van Valen, F., Winkelmann, W., and Jurgens, H. (1992). Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cells. J. Cancer Res. Clin. Oncol. 118, 269-275. doi:10.1007/BF01208615.
105. Wagner, L. M., Smolarek, T. A., Sumegi, J., and Marmer, D. (2012). Assessment of minimal residual disease in Ewing sarcoma. Sarcoma 2012, 780129. doi:10.1155/2012/780129.
106. Wang, X., and Weaver, D. T. (2011). The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am. J. Cancer Res. 1, 301-327.
107. Wang, Z., Wang, F., Tang, T., and Guo, C. (2012). The role of PARP1 in the DNA damage response and its application in tumor therapy. Front. Med. 6:156-164. doi:10.1007/s11684-012-0197-3.
108. Wei, G., Antonescu, C. R., De Alava, E., Leung, D., Huvos, A. G., Meyers, P. A., et al. (2000). Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 89, 793-799. doi:10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M.
109. West, D. C., Grier, H. E., Swallow, M. M., Demetri, G. D., Granowetter, L., and Sklar, J. (1997). Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J. Clin. Oncol. 15, 583-588.
110. Womer, R. B., West, D. C., Krailo, M. D., Dickman, P. S., Pawel, B. R., Grier, H. E., et al. (2012). Randomized Controlled Trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a Report from the Children's Oncology Group. J. Clin. Oncol. 30, 4148-4154. doi:10.1200/JCO.2011.41.5703.
111. Yabe, H., Tsukahara, T., Kawaguchi, S., Wada, T., Sato, N., and Morioka, H. (2008). Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol. Rep. 19, 129-134.
112. Zambelli, D., Zuntini, M., Nardi, F., Manara, M. C., Serra, M., Landuzzi, L., et al. (2010). Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). Int. J. Cancer 126, 41-52. doi:10.1002/ijc.24670.
113. Zielenska, M., Zhang, Z. M., Ng, K., Marrano, P., Bayani, J., Ramirez, O. C., et al. (2001). Acquisition of secondary structural chromosomal changes in pediatric Ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 91, 2156-2164. doi:10.1002/1097-0142(20010601)91:11<2156::AIDCNCR1244>3.0.CO;2-I.
114. Zoubek, A., Dockhorn-Dworniczak, B., Delattre, O., Christiansen, H., Niggli, F., Gatterer-Menz, I., et al. (1996). Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 14, 1245-1251.
115. Zoubek, A., Ladenstein, R., Windhager, R., Amann, G., Fischmeister, G., Kager, L., et al. (1998). Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int. J. Cancer 79, 56-60. doi:10.1002/(SICI)1097-0215(19980220)79:1<56::AID-IJC11>3.0.CO;2-F.